Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXAS NASDAQ:HALO NASDAQ:LGND NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$50.46-3.4%$54.33$39.97▼$72.83$9.85B0.952.57 million shs2.15 million shsHALOHalozyme Therapeutics$56.45-2.4%$54.29$42.01▼$70.51$7.12B1.151.75 million shs1.11 million shsLGNDLigand Pharmaceuticals$139.10+1.1%$112.10$90.29▼$139.53$2.65B0.84119,379 shs347,058 shsRGENRepligen$116.25-6.3%$124.65$102.97▼$182.52$6.97B1.11726,248 shs1.03 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences-2.72%-2.08%-0.63%+25.57%+5.75%HALOHalozyme Therapeutics-0.34%+0.31%+8.85%-1.67%+5.59%LGNDLigand Pharmaceuticals+6.13%+10.07%+22.24%+31.06%+36.11%RGENRepligen+3.58%-7.43%+2.50%-4.58%-6.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXASExact Sciences4.6942 of 5 stars3.55.00.04.72.72.50.6HALOHalozyme Therapeutics4.9625 of 5 stars3.14.00.04.42.92.54.4LGNDLigand Pharmaceuticals3.5289 of 5 stars1.51.00.04.42.13.31.9RGENRepligen4.7212 of 5 stars4.31.00.04.53.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 2.95Moderate Buy$70.5039.71% UpsideHALOHalozyme Therapeutics 2.17Hold$62.7011.07% UpsideLGNDLigand Pharmaceuticals 3.00Buy$147.175.80% UpsideRGENRepligen 2.69Moderate Buy$170.7546.88% UpsideCurrent Analyst Ratings BreakdownLatest LGND, EXAS, RGEN, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$58.00 ➝ $60.007/10/2025HALOHalozyme TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$55.007/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.007/8/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.006/24/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.006/24/2025RGENRepligenBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$150.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.76B3.45$5.44 per share9.27$12.98 per share3.89HALOHalozyme Therapeutics$1.02B6.85$4.54 per share12.43$2.86 per share19.74LGNDLigand Pharmaceuticals$167.13M16.05$1.62 per share85.61$43.95 per share3.16RGENRepligen$634.44M10.29$2.91 per share39.93$35.21 per share3.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$1.03B-$5.51N/A100.9211.15-36.06%-3.75%-1.68%8/6/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$3.7615.019.080.3944.76%136.91%26.05%8/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A37.49N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)RGENRepligen-$25.51M-$0.45N/A49.263.55-3.93%4.53%3.17%7/29/2025 (Estimated)Latest LGND, EXAS, RGEN, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EXASExact Sciences-$0.04N/AN/AN/A$774.43 millionN/A8/5/2025Q2 2025HALOHalozyme Therapeutics$1.22N/AN/AN/A$282.66 millionN/A8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A7/29/2025Q2 2025RGENRepligen$0.40N/AN/AN/A$174.62 millionN/A5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million5/1/2025Q1 2025EXASExact Sciences-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.972.732.38HALOHalozyme Therapeutics3.138.397.30LGNDLigand PharmaceuticalsN/A5.275.02RGENRepligen0.276.795.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%HALOHalozyme Therapeutics97.79%LGNDLigand Pharmaceuticals91.28%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.20%HALOHalozyme Therapeutics2.40%LGNDLigand Pharmaceuticals7.00%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences7,000188.64 million186.37 millionOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableRGENRepligen1,77856.18 million55.51 millionOptionableLGND, EXAS, RGEN, and HALO HeadlinesRecent News About These CompaniesWinners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services StocksJuly 18 at 5:25 PM | msn.com3 Reasons RGEN is Risky and 1 Stock to Buy InsteadJuly 18 at 5:25 PM | msn.comRepligen Corp (RGEN) Trading Down 4.19% on Jul 18July 18 at 1:43 PM | gurufocus.comQ1 Earnings Estimate for Repligen Issued By Leerink PartnrsJuly 18 at 10:53 AM | marketbeat.comRepligen to Report Second Quarter 2025 Financial ResultsJuly 17 at 7:30 AM | globenewswire.comSegall Bryant & Hamill LLC Grows Stake in Repligen Corporation (NASDAQ:RGEN)July 17 at 6:51 AM | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Acquired by Rice Hall James & Associates LLCJuly 15 at 5:45 AM | marketbeat.comRepligen (NASDAQ:RGEN) Trading Down 5.4% - Here's WhyJuly 14, 2025 | marketbeat.comTimesSquare Capital Management LLC Has $30.03 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)July 14, 2025 | marketbeat.comSlow Capital Inc. Has $4.18 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)July 14, 2025 | marketbeat.comNew York State Common Retirement Fund Grows Holdings in Repligen Corporation (NASDAQ:RGEN)July 14, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Bought by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comTeacher Retirement System of Texas Increases Stake in Repligen Corporation (NASDAQ:RGEN)July 11, 2025 | marketbeat.comBanque Pictet & Cie SA Has $3.12 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)July 10, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Position in Repligen Corporation (NASDAQ:RGEN)July 9, 2025 | marketbeat.comRepligen And 2 Other Stocks That May Be Trading Below Estimated ValueJuly 8, 2025 | finance.yahoo.comEvercore ISI Cuts Repligen (NASDAQ:RGEN) Price Target to $130.00July 8, 2025 | marketbeat.comNew York State Teachers Retirement System Has $6.49 Million Holdings in Repligen Corporation (NASDAQ:RGEN)July 6, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 6, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plcJuly 5, 2025 | marketbeat.com1 Healthcare Stock to Target This Week and 2 to Be Wary OfJuly 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesHow Texas Roadhouse Is Winning in a Changing Consumer MarketBy Dan Schmidt | July 14, 2025View How Texas Roadhouse Is Winning in a Changing Consumer MarketTexas Instruments Stock: Congress Likes It, Should You Too?By Thomas Hughes | June 24, 2025View Texas Instruments Stock: Congress Likes It, Should You Too?LGND, EXAS, RGEN, and HALO Company DescriptionsExact Sciences NASDAQ:EXAS$50.46 -1.75 (-3.35%) Closing price 04:00 PM EasternExtended Trading$50.46 -0.01 (-0.01%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Halozyme Therapeutics NASDAQ:HALO$56.45 -1.36 (-2.35%) Closing price 04:00 PM EasternExtended Trading$56.44 -0.01 (-0.01%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Ligand Pharmaceuticals NASDAQ:LGND$139.10 +1.53 (+1.11%) Closing price 04:00 PM EasternExtended Trading$139.14 +0.04 (+0.03%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Repligen NASDAQ:RGEN$116.25 -7.79 (-6.28%) Closing price 04:00 PM EasternExtended Trading$116.61 +0.36 (+0.31%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.